Differentiating the Differentiation Syndrome Associated with IDH Inhibitors in AML.
Joshua F ZeidnerPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Isocitrate dehydrogenase (IDH) inhibitors have clinical activity in acute myeloid leukemia, in part, by differentiating blasts to mature myeloid cells. In the largest systematic analysis to date, differentiation syndrome was seen in 19% of patients treated with IDH inhibitors. Early recognition with uniform diagnostic criteria, as utilized in acute promyelocytic leukemia, may reduce subsequent complications.See related article by Norsworthy et al., p. 4280.
Keyphrases
- acute myeloid leukemia
- low grade
- wild type
- bone marrow
- induced apoptosis
- case report
- dendritic cells
- contrast enhanced
- immune response
- magnetic resonance imaging
- high grade
- drug induced
- magnetic resonance
- intensive care unit
- allogeneic hematopoietic stem cell transplantation
- cell proliferation
- endoplasmic reticulum stress
- acute respiratory distress syndrome
- aortic dissection